Cetuximab biobetter - Mabtech/Sorrento

Drug Profile

Cetuximab biobetter - Mabtech/Sorrento

Alternative Names: STI-001

Latest Information Update: 14 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Antineoplastics; Biobetters; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 29 Jun 2017 Taizhou Mabtech Pharmaceutical plans a phase III trial for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in China (IV) (NCT03206151)
  • 11 Jan 2016 Efficacy and safety data from a phase III trial in Colorectal cancer released by Sorrento Therapeutics
  • 03 Aug 2015 Mabtech announces intention to submit NDA to Chinese FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top